ENKAID is indicated for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of ENKAID, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. ENKAID should not be used in patients with less severe ventricular arrhythmias, even if the patients are symptomatic.
Submit your review
malaise, decreased or increased blood pressure, confusion, ataxia, abnormal gait, abnormal sensation, abnormal dreams, diplopia, photophobia and periorbital edema.
The recommended initial dosing schedule for adults is one 25 mg ENKAID capsule t.i.d. at approximately 8-hour intervals. After a period of 3 to 5 days, the dosage may be increased to 35 mg t.i.d. if necessary. If the desired therapeutic response is not achieved after an additional 3 to 5 days, the dose may again be adjusted to 50 mg t.i.d. Rapid dose escalation should be avoided.